Selective Sirt2 inhibition by ligand-induced rearrangement of the active site

Nature Communications

Volumn 6, Issue , 2015, Pages

  Rumpf, Tobias ^a   Schiedel, Matthias ^a   Karaman, Berin ^b   Roessler, Claudia ^b   North, Brian J ^c   Lehotzky, Attila ^d   Oláh, Judit ^d   Ladwein, Kathrin I ^a   Schmidtkunz, Karin ^a   Gajer, Markus ^a   Pannek, Martin ^e   Steegborn, Clemens ^e   Sinclair, David A ^c   Gerhardt, Stefan ^a   Ovádi, Judit ^d   Schutkowski, Mike ^b   Sippl, Wolfgang ^b   Einsle, Oliver ^a   Jung, Manfred ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; LIGAND; SIRTUIN 2; TUBULIN; ACETAMIDE DERIVATIVE; ENZYME INHIBITOR; PROTEIN BINDING; SIRREAL2; SIRT2 PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

CANCER; CELL ORGANELLE; DRUG; INHIBITOR; LIGAND; PATHOGENICITY; STABILIZATION;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; FEMALE; GENE REARRANGEMENT; HELA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; PROTEIN ACETYLATION; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME ACTIVE SITE; KINETICS; MOLECULAR GENETICS; MOLECULAR MODEL; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ACETAMIDES; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; SIRTUIN 2; THIAZOLES;

EID: 84923169946     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7263     Document Type: Article

References (68)

1. Feldman, J. L., Baeza, J. & Denu, J. M. Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J. Biol. Chem. 288, 31350-31356 (2013).
2. Jiang, H. et al. SIRT6 regulates TNF-a secretion through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110-113 (2013).
3. Du, J. et al. Sirt5 Is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334, 806-809 (2011).
4. Du, J., Jiang, H. & Lin, H. Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD. Biochemistry 48, 2878-2890 (2009).
5. Vaquero, A., Sternglanz, R. & Reinberg, D. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 26, 5505-5520 (2007).
6. North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M. & Verdin, E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 11, 437-444 (2003).
7. Beirowski, B. et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc. Natl Acad. Sci. USA 108, E952-E961 (2011).
8. de Oliveira, R. M., Sarkander, J., Kazantsev, A. G. & Outeiro, T. F. SIRT2 as a therapeutic target for age-related disorders. Front. Pharmacol. 3, 82 (2012).
9. Pais, T. F. et al. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J. 32, 2603-2616 (2013).
10. Kim, H.-S. et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20, 487-499 (2011).
11. Serrano, L. et al. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes Dev. 27, 639-653 (2013).
12. Yang, M. H. et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol. Cancer Res. 11, 1072-1077 (2013).
13. Liu, P. Y. et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20, 503-514 (2013).
14. Eskandarian, H. A. et al. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. Science 341, 1238858-1238858 (2013).
15. Outeiro, T. F. et al. Sirtuin 2 inhibitors rescue a-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519 (2007).
16. Chopra, V. et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2, 1492-1497 (2012).
17. Bobrowska, A., Donmez, G., Weiss, A., Guarente, L. & Bates, G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS ONE 7, e34805 (2012).
18. Finnin, M. S., Donigian, J. R. & Pavletich, N. P. Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 8, 621-625 (2001).
19. Moniot, S., Schutkowski, M. & Steegborn, C. Crystal structure analysis of human Sirt2 and its ADP-ribose complex. J. Struct. Biol. 182, 136-143 (2013).
20. Jin, L. et al. Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J. Biol. Chem. 284, 24394-24405 (2009).
21. Davenport, A. M., Huber, F. M. & Hoelz, A. Structural and Functional Analysis of Human SIRT1. J. Mol. Biol. 426, 526-541 (2014).
22. Pan, P. W. et al. Structure and biochemical functions of SIRT6. J. Biol. Chem. 286, 14575-14587 (2011).
23. Szczepankiewicz, B. G. et al. Synthesis of carba-NAD and the structures of its ternary complexes with SIRT3 and SIRT5. J. Org. Chem. 77, 7319-7329 (2012).
24. Suzuki, T. et al. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. J. Med. Chem. 55, 5760-5773 (2012).
25. Napper, A. D. et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48, 8045-8054 (2005).
26. Hoffmann, G., Breitenbücher, F., Schuler, M. & Ehrenhofer-Murray, A. E. A novel sirtuin 2 (SIRT2) Inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J. Biol. Chem. 289, 5208-5216 (2014).
27. Cui, H. et al. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. J. Med. Chem. 57, 8340-8357 (2014).
28. Yamagata, K. et al. Structural basis for potent inhibition of SIRT2 deacetylase by a macrocyclic peptide inducing dynamic structural change. Structure 22, 345-352 (2014).
29. Heltweg, B., Trapp, J. & Jung, M. In vitro assays for the determination of histone deacetylase activity. Methods 36, 332-337 (2005).
30. Avalos, J. L., Bever, K. M. & Wolberger, C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+ cosubstrate specificity of a Sir2 enzyme. Mol. Cell 17, 855-868 (2005).
31. Avalos, J. L. et al. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell 10, 523-535 (2002).
32. Cosgrove, M. S. et al. The structural basis of sirtuin substrate affinity. Biochemistry 45, 7511-7521 (2006).
33. Gertz, M. et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc. Natl Acad. Sci. USA 110, E2772-E2781 (2013).
34. Hoff, K. G., Avalos, J. L., Sens, K. & Wolberger, C. Insights into the sirtuin mechanism from ternary complexes containing NAD+ and acetylated peptide. Structure 14, 1231-1240 (2006).
35. Di Tommaso, P. et al. T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. Nucleic Acids Res. 39, W13-W17 (2011).
36. Frye, R. A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793-798 (2000).
37. Trapp, J. et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem. 49, 7307-7316 (2006).
38. Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458 (2002).
39. Mangas-Sanjuan, V. et al. Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. Br. J. Pharmacol. 172, 829-840 (2014).
40. Tokési, N. et al. TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6. J. Biol. Chem. 285, 17896-17906 (2010).
41. North, B. J. et al. SIRT2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO J. 33, 1438-1453 (2014).
42. Baker, D. J. et al. Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat. Cell Biol. 15, 96-102 (2013).
43. Sakaguchi, K. et al. DNA damage activates p53 through a phosphorylationacetylation cascade. Genes Dev. 12, 2831-2841 (1998).
44. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159 (2001).
45. Luo, J. et al. Negative control of p53 by Sir2a promotes cell survival under stress. Cell 107, 137-148 (2001).
46. Lombard, D. B. et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 27, 8807-8814 (2007).
47. Schuetz, A. et al. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 15, 377-389 (2007).
48. Zhao, X. et al. The 2.5Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J. Med. Chem. 56, 963-969 (2013).
49. Nguyen, G. T. T., Schaefer, S., Gertz, M., Weyand, M. & Steegborn, C. Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: binding details and inhibition mechanism. Acta Crystallogr. D Biol. Crystallogr. 69, 1423-1432 (2013).
50. Nguyen, G. T. T., Gertz, M. & Steegborn, C. Crystal structures of Sirt3 complexes with 4'-bromo-resveratrol reveal binding sites and inhibition mechanism. Chem. Biol. 20, 1375-1385 (2013).
51. Disch, J. S. et al. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3. J. Med. Chem. 56, 3666-3679 (2013).
52. Maurer, B., Rumpf, T., Scharfe, M. & Stolfa, D. A. Inhibitors of the NAD+dependent protein desuccinylase and demalonylase Sirt5. ACS Med. Chem. Lett. 12, 1050-1053 (2012).
53. Schlicker, C., Boanca, G., Lakshminarasimhan, M. & Steegborn, C. Structure-based development of novel sirtuin inhibitors. Aging 3, 852-872 (2011).
54. Laurent, G. et al. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol. Cell 50, 686-698 (2013).
55. MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968 (2010).
56. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
57. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
58. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030-1033 (2012).
59. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22-25 (2010).
60. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
61. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
62. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
63. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
64. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
65. Krissinel, E. Enhanced fold recognition using efficient short fragment clustering. J. Mol. Biochem. 1, 76-85 (2012).
66. Ho, B. K. & Gruswitz, F. HOLLOW: generating accurate representations of channel and interior surfaces in molecular structures. BMC Struct. Biol. 8, 49 (2008).
67. Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778-2786 (2011).
68. Niesen, F. H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212-2221 (2007).